1
|
Pingale P, Kendre P, Pardeshi K, Rajput A. An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques. Heliyon 2023; 9:e14247. [PMID: 36938476 PMCID: PMC10018573 DOI: 10.1016/j.heliyon.2023.e14247] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Revised: 02/10/2023] [Accepted: 02/28/2023] [Indexed: 03/07/2023] Open
Abstract
Nanotechnology has the capability of making significant contributions to healthcare. Nanofabrication of multifunctional nano- or micro-character systems is becoming incredibly influential in various sectors like electronics, photonics, energy, and biomedical gadgets worldwide. The invention of such items led to the merger of moderate cost and excellent quality nano or micro-characters into 3D structures. Nanofabrication techniques have many benefits as the primary technology for manipulating cellular surroundings to research signaling processes. The inherent nanoscale mechanisms of cyto-reactions include the existence and death of cells, stem cell segmentation, multiplication, cellular relocation, etc. Nanofabrication is essential in developing various nano-formulations like solid lipid nanoparticles, nanostructured lipid carriers, liposomes, niosomes, nanoemulsions, microemulsions etc. Despite the initial development cost in designing the nanofabrication-based products, it has also reduced the total cost of the healthcare system by considering the added benefits compared to the other standard formulations. Thus, the current review mainly focuses on nanofabrication techniques, advantages, disadvantages, applications in developing various nanocarrier systems, challenges and future perspectives.
Collapse
Affiliation(s)
- Prashant Pingale
- Department of Pharmaceutics, GES's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik 422005, Maharashtra, India
| | - Prakash Kendre
- Department of Pharmaceutics, Rajarshi Shahu College of Pharmacy, At Post-Malvihir, Botha Road, Tal. Buldana, Dist. Buldana, 422005, Maharashtra, India
| | - Krutika Pardeshi
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Sandip University, Nashik 422231, Maharashtra, India
| | - Amarjitsing Rajput
- Department of Pharmaceutics, Bharti Vidyapeeth Deemed University, Poona College of Pharmacy, Bharti Vidyapeeth Educational Complex, Erandwane, Pune 411038, Maharashtra, India
| |
Collapse
|
2
|
Tomsen-Melero J, Merlo-Mas J, Carreño A, Sala S, Córdoba A, Veciana J, González-Mira E, Ventosa N. Liposomal formulations for treating lysosomal storage disorders. Adv Drug Deliv Rev 2022; 190:114531. [PMID: 36089182 DOI: 10.1016/j.addr.2022.114531] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 05/13/2022] [Accepted: 09/04/2022] [Indexed: 01/24/2023]
Abstract
Lysosomal storage disorders (LSD) are a group of rare life-threatening diseases caused by a lysosomal dysfunction, usually due to the lack of a single enzyme required for the metabolism of macromolecules, which leads to a lysosomal accumulation of specific substrates, resulting in severe disease manifestations and early death. There is currently no definitive cure for LSD, and despite the approval of certain therapies, their effectiveness is limited. Therefore, an appropriate nanocarrier could help improve the efficacy of some of these therapies. Liposomes show excellent properties as drug carriers, because they can entrap active therapeutic compounds offering protection, biocompatibility, and selectivity. Here, we discuss the potential of liposomes for LSD treatment and conduct a detailed analysis of promising liposomal formulations still in the preclinical development stage from various perspectives, including treatment strategy, manufacturing, characterization, and future directions for implementing liposomal formulations for LSD.
Collapse
Affiliation(s)
- Judit Tomsen-Melero
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red - Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain
| | | | - Aida Carreño
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red - Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain
| | - Santi Sala
- Nanomol Technologies SL, 08193 Cerdanyola del Vallès, Spain
| | - Alba Córdoba
- Nanomol Technologies SL, 08193 Cerdanyola del Vallès, Spain
| | - Jaume Veciana
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red - Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain
| | - Elisabet González-Mira
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red - Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
| | - Nora Ventosa
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red - Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
| |
Collapse
|
3
|
Ferrer‐Tasies L, Santana H, Cabrera‐Puig I, González‐Mira E, Ballell‐Hosa L, Castellar‐Álvarez C, Córdoba A, Merlo‐Mas J, Gerónimo H, Chinea G, Falcón V, Moreno‐Calvo E, Pedersen JS, Romero J, Navarro‐Requena C, Valdés C, Limonta M, Berlanga J, Sala S, Martínez E, Veciana J, Ventosa N. Recombinant Human Epidermal Growth Factor/Quatsome Nanoconjugates: A Robust Topical Delivery System for Complex Wound Healing. ADVANCED THERAPEUTICS 2021. [DOI: 10.1002/adtp.202000260] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Lidia Ferrer‐Tasies
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
- Nanomol Technologies S.L. Campus UAB Bellaterra 08193 Spain
| | - Hector Santana
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Ingrid Cabrera‐Puig
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
| | - Elisabet González‐Mira
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
| | - Lídia Ballell‐Hosa
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
- Nanomol Technologies S.L. Campus UAB Bellaterra 08193 Spain
| | | | - Alba Córdoba
- Nanomol Technologies S.L. Campus UAB Bellaterra 08193 Spain
| | | | - Haydee Gerónimo
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Glay Chinea
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Viviana Falcón
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Evelyn Moreno‐Calvo
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
| | - Jan Skov Pedersen
- Department of Chemistry and Interdisciplinary Nanoscience Center (iNANO) Aarhus University Gustav Wieds Vej 14 Aarhus C DK‐8000 Denmark
| | - Jessica Romero
- Health and Biomedicine Unit LEITAT Technological Center C/ de la Innovació, 2 Terrassa Barcelona 08225 Spain
| | - Claudia Navarro‐Requena
- Health and Biomedicine Unit LEITAT Technological Center C/ de la Innovació, 2 Terrassa Barcelona 08225 Spain
| | - Calixto Valdés
- National Institute for Angiology and Vascular Surgery 1551 Calzada del Cerro, Cerro Havana 12000 Cuba
| | - Miladys Limonta
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Jorge Berlanga
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Santiago Sala
- Nanomol Technologies S.L. Campus UAB Bellaterra 08193 Spain
| | - Eduardo Martínez
- Center for Genetic Engineering and Biotechnology (CIGB) 31st Avenue between 158 and 190 Streets, Cubanacán, Playa Havana 10600 Cuba
| | - Jaume Veciana
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
| | - Nora Ventosa
- Institut de Ciència de Materials de Barcelona ICMAB‐CSIC/CIBER‐BBN Campus Universitari Bellaterra 08193 Spain
| |
Collapse
|
4
|
Tomsen-Melero J, Passemard S, García-Aranda N, Díaz-Riascos ZV, González-Rioja R, Nedergaard Pedersen J, Lyngsø J, Merlo-Mas J, Cristóbal-Lecina E, Corchero JL, Pulido D, Cámara-Sánchez P, Portnaya I, Ionita I, Schwartz S, Veciana J, Sala S, Royo M, Córdoba A, Danino D, Pedersen JS, González-Mira E, Abasolo I, Ventosa N. Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment. ACS APPLIED MATERIALS & INTERFACES 2021; 13:7825-7838. [PMID: 33583172 DOI: 10.1021/acsami.0c16871] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Fabry disease is a rare lysosomal storage disorder characterized by a deficiency of α-galactosidase A (GLA), a lysosomal hydrolase. The enzyme replacement therapy administering naked GLA shows several drawbacks including poor biodistribution, limited efficacy, and relatively high immunogenicity in Fabry patients. An attractive strategy to overcome these problems is the use of nanocarriers for encapsulating the enzyme. Nanoliposomes functionalized with RGD peptide have already emerged as a good platform to protect and deliver GLA to endothelial cells. However, low colloidal stability and limited enzyme entrapment efficiency could hinder the further pharmaceutical development and the clinical translation of these nanoformulations. Herein, the incorporation of the cationic miristalkonium chloride (MKC) surfactant to RGD nanovesicles is explored, comparing two different nanosystems-quatsomes and hybrid liposomes. In both systems, the positive surface charge introduced by MKC promotes electrostatic interactions between the enzyme and the nanovesicles, improving the loading capacity and colloidal stability. The presence of high MKC content in quatsomes practically abolishes GLA enzymatic activity, while low concentrations of the surfactant in hybrid liposomes stabilize the enzyme without compromising its activity. Moreover, hybrid liposomes show improved efficacy in cell cultures and a good in vitro/in vivo safety profile, ensuring their future preclinical and clinical development.
Collapse
Affiliation(s)
- Judit Tomsen-Melero
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| | - Solène Passemard
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| | - Natalia García-Aranda
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Drug Delivery and Targeting, and Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Zamira Vanessa Díaz-Riascos
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Drug Delivery and Targeting, and Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Ramon González-Rioja
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| | - Jannik Nedergaard Pedersen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
- Department of Chemistry, Aarhus University, Langelandsgade 140, DK-8000 Aarhus C, Denmark
| | - Jeppe Lyngsø
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
- Department of Chemistry, Aarhus University, Langelandsgade 140, DK-8000 Aarhus C, Denmark
| | - Josep Merlo-Mas
- Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain
| | - Edgar Cristóbal-Lecina
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Institut de Química Avançada de Catalunya (IQAC-CSIC), 08034 Barcelona, Spain
| | - José Luis Corchero
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Departament de Genètica i de Microbiologia, Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Daniel Pulido
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Institut de Química Avançada de Catalunya (IQAC-CSIC), 08034 Barcelona, Spain
| | - Patricia Cámara-Sánchez
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Drug Delivery and Targeting, and Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Irina Portnaya
- CryoEM Laboratory of Soft Matter, Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, 32000 Haifa, Israel
| | - Inbal Ionita
- CryoEM Laboratory of Soft Matter, Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, 32000 Haifa, Israel
| | - Simó Schwartz
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Drug Delivery and Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Jaume Veciana
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| | - Santi Sala
- Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain
| | - Miriam Royo
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Institut de Química Avançada de Catalunya (IQAC-CSIC), 08034 Barcelona, Spain
| | - Alba Córdoba
- Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain
| | - Dganit Danino
- CryoEM Laboratory of Soft Matter, Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, 32000 Haifa, Israel
- Faculty of Biotechnology and Food Engineering, Guangdong Technion-Israel Institute of Technology, Daxue Road, Shantou 515063, Guangdong Province, China
| | - Jan Skov Pedersen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
- Department of Chemistry, Aarhus University, Langelandsgade 140, DK-8000 Aarhus C, Denmark
| | - Elisabet González-Mira
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| | - Ibane Abasolo
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
- Drug Delivery and Targeting, and Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Nora Ventosa
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain
| |
Collapse
|
5
|
Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019; 14:93-126. [PMID: 30451076 PMCID: PMC6391637 DOI: 10.2217/nnm-2018-0120] [Citation(s) in RCA: 333] [Impact Index Per Article: 55.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 10/15/2018] [Indexed: 12/23/2022] Open
Abstract
There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.
Collapse
Affiliation(s)
- Fatemeh Farjadian
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran
| | - Amir Ghasemi
- Department of Materials Science & Engineering, Sharif University of Technology, Tehran 11365-9466, Iran
- Advances Nanobiotechnology & Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran 14496-4535, Iran
| | - Omid Gohari
- Department of Materials Science & Engineering, Sharif University of Technology, Tehran 11365-9466, Iran
| | - Amir Roointan
- Department of Medical Biotechnology, School of Advanced Medical Sciences & Technologies, Shiraz University of Medical Science, Shiraz 71348-14336, Iran
| | - Mahdi Karimi
- Cellular & Molecular Research Center, Iran University of Medical Sciences, Tehran 14496-14535, Iran
- Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 14496-14535, Iran
- Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Michael R Hamblin
- Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
- Harvard – MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA
| |
Collapse
|
6
|
Abstract
European countries have invested heavily in Nanomedicine over the last decade, however, the output has been much reduced by a lack of knowledge of how to innovate in a heavily regulated setting. This development failing is not unique to nanomedicine but is there to differing extents across most open innovation healthcare projects. The transition from research to development requires informed debate and high-quality data and is a very challenging milestone. Researchers often say they are developing a new drug, when they are in fact doing research – funders also use the terms (R or D) interchangeably - an unfortunate consequence of their academic training. A simple test is if you don’t know actually what you are developing - you are in research.
Collapse
|
7
|
Cano M, Núñez-Lozano R, Lumbreras R, González-Rodríguez V, Delgado-García A, Jiménez-Hoyuela JM, de la Cueva-Méndez G. Partial PEGylation of superparamagnetic iron oxide nanoparticles thinly coated with amine-silane as a source of ultrastable tunable nanosystems for biomedical applications. NANOSCALE 2017; 9:812-822. [PMID: 27982150 DOI: 10.1039/c6nr07462f] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The development of superparamagnetic iron oxide nanoparticle (SPION)-based diagnostic and therapeutic nanosystems holds a promise of revolutionizing biomedicine, helping to solve important unmet clinical needs. Such potential will only be fulfilled if appropriate methods for SPION production and for their subsequent tailoring to specific applications are established, something that remains challenging. Here, we report a simple and low cost method to fabricate structurally and colloidally ultrastable, water soluble SPIONs. We used thermal decomposition to produce SPIONs of the highest quality, which were then thinly coated with an amine-silane derivative by ligand exchange, conferring hydrophilicity and great structural stability on the nanoparticles. Subsequent partial covalent occupancy of surface amine groups with polyethyleneglycol (PEG) was carried out to give them excellent colloidal stability, whilst still leaving reactive anchoring points for further functionalization. The correct composition and physicochemical properties of our PEGylated SPIONs and their precursors were confirmed using a broad range of analytical techniques, and we also demonstrated the biocompatible character of the resulting nanoparticles, as well as their suitability as T2 MRI contrast agents in vivo. Finally, using a near infra-red fluorophore, we also confirmed that these SPIONs are amenable to further tuning, to adapt them to a wide range of applications or to optimize their performance in particular settings. In summary, our work provides a novel and robust method for the production of SPIONs that can be used as a tunable platform for the development of smart diagnostic and therapeutic nanosystems.
Collapse
Affiliation(s)
- Manuel Cano
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Severo Ochoa 35, 29590 Campanillas, Málaga, Spain. and Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain
| | - Rebeca Núñez-Lozano
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Severo Ochoa 35, 29590 Campanillas, Málaga, Spain. and Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain
| | - Rocío Lumbreras
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Severo Ochoa 35, 29590 Campanillas, Málaga, Spain.
| | - Verena González-Rodríguez
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Severo Ochoa 35, 29590 Campanillas, Málaga, Spain. and Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain and Servicio de Medicina Nuclear, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain
| | - Alberto Delgado-García
- Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain and Servicio de Medicina Nuclear, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain
| | - José Manuel Jiménez-Hoyuela
- Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain and Servicio de Medicina Nuclear, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain
| | - Guillermo de la Cueva-Méndez
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Severo Ochoa 35, 29590 Campanillas, Málaga, Spain. and Institute of Biomedical Research in Málaga, IBIMA, Avda. Jorge Luis Borges 15, Bloque 3, Planta 3ª, 29010 Málaga, Spain
| |
Collapse
|
8
|
Satalkar P, Elger BS, Shaw DM. Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter? SCIENCE AND ENGINEERING ETHICS 2016; 22:1255-1276. [PMID: 26373718 DOI: 10.1007/s11948-015-9705-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 09/10/2015] [Indexed: 06/05/2023]
Abstract
Nanotechnology, which involves manipulation of matter on a 'nano' scale, is considered to be a key enabling technology. Medical applications of nanotechnology (commonly known as nanomedicine) are expected to significantly improve disease diagnostic and therapeutic modalities and subsequently reduce health care costs. However, there is no consensus on the definition of nanotechnology or nanomedicine, and this stems from the underlying debate on defining 'nano'. This paper aims to present the diversity in the definition of nanomedicine and its impact on the translation of basic science research in nanotechnology into clinical applications. We present the insights obtained from exploratory qualitative interviews with 46 stakeholders involved in translational nanomedicine from Europe and North America. The definition of nanomedicine has implications for many aspects of translational research including: fund allocation, patents, drug regulatory review processes and approvals, ethical review processes, clinical trials and public acceptance. Given the interdisciplinary nature of the field and common interest in developing effective clinical applications, it is important to have honest and transparent communication about nanomedicine, its benefits and potential harm. A clear and consistent definition of nanomedicine would significantly facilitate trust among various stakeholders including the general public while minimizing the risk of miscommunication and undue fear of nanotechnology and nanomedicine.
Collapse
Affiliation(s)
- Priya Satalkar
- Institute for Biomedical Ethics (IBMB), University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.
| | - Bernice Simone Elger
- Institute for Biomedical Ethics (IBMB), University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland
| | - David M Shaw
- Institute for Biomedical Ethics (IBMB), University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland
| |
Collapse
|
9
|
Gaudin A, Andrieux K, Couvreur P. Nanomedicines and stroke: Toward translational research. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.07.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Eaton MAW, Levy L, Fontaine OMA. Delivering nanomedicines to patients: a practical guide. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:983-92. [PMID: 25724929 DOI: 10.1016/j.nano.2015.02.004] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Revised: 02/10/2015] [Accepted: 02/14/2015] [Indexed: 11/28/2022]
Abstract
UNLABELLED This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM). FROM THE CLINICAL EDITOR The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved.
Collapse
Affiliation(s)
- Mike A W Eaton
- European Technology Platform on Nanomedicine - ETPN, ETPN Secretariat c/o VDI-VDE Innovation+Technik GmbH, Berlin, Germany.
| | | | - Olivier M A Fontaine
- European Technology Platform on Nanomedicine - ETPN, ETPN Secretariat c/o VDI-VDE Innovation+Technik GmbH, Berlin, Germany
| |
Collapse
|
11
|
Conejos-Sánchez I, Cardoso I, Oteo-Vives M, Romero-Sanz E, Paul A, Sauri AR, Morcillo MA, Saraiva MJ, Vicent MJ. Polymer-doxycycline conjugates as fibril disrupters: an approach towards the treatment of a rare amyloidotic disease. J Control Release 2014; 198:80-90. [PMID: 25481444 DOI: 10.1016/j.jconrel.2014.12.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Revised: 11/01/2014] [Accepted: 12/02/2014] [Indexed: 10/24/2022]
Abstract
The term amyloidosis describes neurological diseases where an abnormal protein is misfolded and accumulated as deposits in organs and tissues, known as amyloid, disrupting their normal function. In the most common familial amyloid polyneuropathy (FAP), transthyretin (TTR) displays this role primarily affecting the peripheral nervous system (PNS). Advanced stages of this inherited rare amyloidosis, present as fibril deposits that are responsible for disease progression. In order to stop disease progression, herein we designed an efficient family of nanoconjugates as fibril disrupters. These polymer conjugates are based on doxycycline (doxy), already in phase II trials for Alzheimer's disease, covalently linked to poly-l-glutamic acid (PGA). The conjugates were rationally designed, looking at drug loading and drug release rate by adequate linker design, always considering the physiological conditions at the molecular target site. Conjugation of doxycycline exhibited greater potential towards TTR fibril disaggregation in vitro compared to the parent drug. Exhaustive physico-chemical evaluation of these polymer-drug conjugates concluded that drug release was unnecessary for activity, highlighting the importance of an appropriate linker. Furthermore, biodistribution studies through optical imaging (OI) and the use of radiolabelled polymer-drug conjugates demonstrated conjugate safety profile and renal clearance route of the selected PGA-doxy candidate, settling the adequacy of our conjugate for future in vivo evaluation. Furthermore, preliminary studies in an FAP in vivo model at early stages of disease development showed non-organ toxicity evidences. This nanosized-system raises a promising treatment for advanced stages of this rare amyloidotic disease, and also presents a starting point for possible application within other amyloidosis-related diseases, such as Alzheimer's disease.
Collapse
Affiliation(s)
- Inmaculada Conejos-Sánchez
- Polymer Therapeutics Lab., Centro de Investigación Príncipe Felipe (CIPF), Av. Eduardo Primo Yúfera 3, Valencia 46012, Spain
| | - Isabel Cardoso
- Instituto de Biología Molecular e Celular (IBMC), Rua do Campo Alegre 823, Porto 4150-180, Portugal
| | - Marta Oteo-Vives
- Biomedical Applications of Radioisotopes and Pharmacokinetics Unit, CIEMAT, Av. Complutense 40, Madrid 28040, Spain
| | - Eduardo Romero-Sanz
- Biomedical Applications of Radioisotopes and Pharmacokinetics Unit, CIEMAT, Av. Complutense 40, Madrid 28040, Spain
| | - Alison Paul
- School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom
| | - Amparo Ruiz Sauri
- Pathology Department, University of Valencia, Blasco Ibáñez 15, Valencia 46010, Spain
| | - Miguel A Morcillo
- Biomedical Applications of Radioisotopes and Pharmacokinetics Unit, CIEMAT, Av. Complutense 40, Madrid 28040, Spain
| | - Maria J Saraiva
- Instituto de Biología Molecular e Celular (IBMC), Rua do Campo Alegre 823, Porto 4150-180, Portugal
| | - María J Vicent
- Polymer Therapeutics Lab., Centro de Investigación Príncipe Felipe (CIPF), Av. Eduardo Primo Yúfera 3, Valencia 46012, Spain.
| |
Collapse
|
12
|
Cabrera I, Elizondo E, Esteban O, Corchero JL, Melgarejo M, Pulido D, Córdoba A, Moreno E, Unzueta U, Vazquez E, Abasolo I, Schwartz S, Villaverde A, Albericio F, Royo M, García-Parajo MF, Ventosa N, Veciana J. Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. NANO LETTERS 2013; 13:3766-74. [PMID: 23829208 DOI: 10.1021/nl4017072] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The integration of therapeutic biomolecules, such as proteins and peptides, in nanovesicles is a widely used strategy to improve their stability and efficacy. However, the translation of these promising nanotherapeutics to clinical tests is still challenged by the complexity involved in the preparation of functional nanovesicles and their reproducibility, scalability, and cost production. Here we introduce a simple one-step methodology based on the use of CO2-expanded solvents to prepare multifunctional nanovesicle-bioactive conjugates. We demonstrate high vesicle-to-vesicle homogeneity in terms of size and lamellarity, batch-to-batch consistency, and reproducibility upon scaling-up. Importantly, the procedure is readily amenable to the integration/encapsulation of multiple components into the nanovesicles in a single step and yields sufficient quantities for clinical research. The simplicity, reproducibility, and scalability render this one-step fabrication process ideal for the rapid and low-cost translation of nanomedicine candidates from the bench to the clinic.
Collapse
Affiliation(s)
- Ingrid Cabrera
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus Universitari de Bellaterra, 08193 Cerdanyola del Vallès, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
te Kulve H, Rip A. Economic and societal dimensions of nanotechnology-enabled drug delivery. Expert Opin Drug Deliv 2013; 10:611-22. [DOI: 10.1517/17425247.2013.770467] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|